Research analysts at StockNews.com initiated coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a report issued on Sunday. The brokerage set a "buy" rating on the medical instruments supplier's stock.

Pro-Dex Trading Up 7.5 %

Shares of PDEX stock opened at $17.20 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.39 and a current ratio of 2.73. Pro-Dex has a 1 year low of $12.40 and a 1 year high of $26.50. The stock has a fifty day moving average of $17.08 and a two-hundred day moving average of $17.35. The firm has a market capitalization of $61.58 million, a PE ratio of 16.54 and a beta of 0.94.

Get Pro-Dex alerts:

Pro-Dex (NASDAQ:PDEX – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The medical instruments supplier reported $0.29 earnings per share (EPS) for the quarter. Pro-Dex had a return on equity of 16.75% and a net margin of 8.97%. The company had revenue of $11.09 million during the quarter.

Institutional Trading of Pro-Dex

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of Pro-Dex by 2.7% during the third quarter. Dimensional Fund Advisors LP now owns 58,126 shares of the medical instruments supplier's stock worth $1,030,000 after purchasing an additional 1,535 shares during the period. LSV Asset Management raised its position in shares of Pro-Dex by 13.9% during the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock worth $588,000 after purchasing an additional 4,346 shares during the period. JPMorgan Chase & Co. raised its position in shares of Pro-Dex by 59.2% during the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 7,762 shares during the period. State Street Corp raised its position in shares of Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock worth $197,000 after purchasing an additional 650 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pro-Dex during the second quarter worth $168,000. Institutional investors own 13.49% of the company's stock.

About Pro-Dex

(Get Rating)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Further Reading

• Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
• MarketBeat: Week in Review 01/02-01/06
• Why is the CrowdStrike Stock Price Struggling?
• Four Undervalued Healthcare Stocks for 2023
• WWE Stock: Vince McMahon Wants Back In The Show
• NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.